Novartis AG: There is still some upside potential
| Entry price | Target | Stop-loss | Potential |
|---|
|
CHF 99.07 |
CHF 108 |
CHF 95 |
+9.01% |
|---|
Shares in Novartis AG do not show any sign of a slowdown in the ascending dynamic. Investors could bet on a continuation of the underlying trend.
Summary● The company has a good ESG score relative to its sector, according to Refinitiv.
● Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
● Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
● Over the last twelve months, the sales forecast has been frequently revised upwards.
● Sales forecast by analysts have been recently revised upwards.
● Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
● The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
● The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
● The company's "enterprise value to sales" ratio is among the highest in the world.
● The company appears highly valued given the size of its balance sheet.
● The group usually releases earnings worse than estimated.
© MarketScreener.com -
2024
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener UK. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.
Surperformance is Buy on NOVARTIS AG since 10/06/2025
.
